According to the new rules for overseas listing filing of domestic enterprises that took effect on March 31, 2023, when enterprises choose to list via H shares in Hong Kong, the old "small and large approval slips" have become history. Enterprises can directly submit their prospectuses for overseas listing, and the "large approval slip" will be replaced by a "filing notice". Recently, the Department of International Cooperation of the China Securities Regulatory Commission (CSRC) issued the Filing Notice for Overseas Issuance and Listing of Cloudbreak Pharma Inc. (Bokangshiyun) (Guohe Han [2024] No. 2262). Cloudbreak Pharma Inc. (Bokangshiyun): We have received the filing materials for your company's overseas initial public offering submitted through its domestic operating entity, Bokangshiyun Biomedical Technology (Suzhou) Co., Ltd. Pursuant to the Securities Law of the People's Republic of China, the Interim Measures for the Administration of Overseas Issuance of Securities and Listing by Domestic Enterprises and other relevant provisions, we hereby notify you of the filing matters as follows: 1. Your company intends to issue no more than 133,361,700 overseas listed common shares and list on The Stock Exchange of Hong Kong Limited (HKEX). 2. From the date of issuance of this filing notice until the completion of this overseas issuance and listing, if any material event occurs to your company, you shall report it through the CSRC Filing Management Information System in accordance with the relevant provisions on overseas issuance and listing of domestic enterprises. 3. Within 15 working days after the completion of your company's overseas issuance and listing, you shall report the issuance and listing situation through the CSRC Filing Management Information System. During the process of overseas issuance and listing, your company shall strictly comply with the relevant laws, regulations and rules at home and abroad. 4. If your company fails to complete the overseas issuance and listing within 12 months from the date of issuance of this filing notice and intends to continue the process, you shall update the filing materials. This filing notice only confirms the filing information for the company's overseas issuance and listing, and does not mean that the CSRC has made a substantive judgment or guarantee on the investment value of the company's securities or the returns of investors, nor does it mean that the CSRC guarantees or confirms the truthfulness, accuracy and completeness of the company's filing materials. December 10, 2024 Bokangshiyun submitted its prospectus to HKEX on December 2, 2024. Its main intermediary team for the listing includes: UBS, CCB International and Huatai International as its joint sponsors; PwC as its auditor; Haiwen & Partners and Hogan Lovells as its Chinese legal counsel and Hong Kong and U.S. legal counsel for the company respectively; Jingtian & Gongcheng and Ashurst as its Chinese legal counsel and Hong Kong and U.S. legal counsel for the underwriters respectively; Frost & Sullivan as its industry consultant. Founded in 2015, Bokangshiyun is an innovation-driven clinical-stage ophthalmic biotech company dedicated to developing novel and differentiated therapies. For years, the company has focused on internally discovering, developing and commercializing first-in-class and best-in-class ophthalmic therapies. Bokangshiyun has established a broad and innovative pipeline consisting of eight drug candidates covering major anterior and posterior segment eye diseases, among which four candidates are in clinical stage and four are in pre-clinical stage. According to the prospectus, in the pre-listing shareholding structure of Bokangshiyun, Dr. Ni Jinsong and Ms. Bing Leng, a couple, hold 22.18% of the shares in total; Mr. Van Son Dinh holds 7.39%; Dr. Yang Rong holds 1.76%; Dr. Li Jun Zhi holds 4.14%; Other shareholders include Aomei, CDH Investments, Yicun Capital, Gaotejia, Whitcup Life, Far East Union Health (00512.HK), CCB International, Deyi Evergreen, Brillimedical, Saier Holdings, Guanzi Equity, Hainan Yifeng, K. RUI, Yunxin, CNCB, Tianchuang Innovation, Xiao Shuilong, Chuangdongfang Changhui, BOC International, Beijing Jiurunda, Yingke Dezhi Puze, Yunwen, Jiangmen Yifeng, Industrial Securities (601377.SH), Dr. John Hovanesian, etc. https://www1.hkexnews.hk/app/sehk/2024/106945/documents/sehk24120204025.pdf © 2021 Meishun (Hong Kong) Management Consulting Co., Ltd. and Meishun (Hangzhou) Management Consulting Co., Ltd. All rights reserved. Meishun Meiyin (Hangzhou) Consulting Management Co., Ltd. is a domestic subsidiary of Hong Kong Meishun Management Consulting Company under the same actual controller. Both companies are under the same actual controller, managed under the principle of "One China", and comply with the laws of Hong Kong and the mainland of China.